1. Home
  2. HRMY vs LMAT Comparison

HRMY vs LMAT Comparison

Compare HRMY & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$38.49

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo LeMaitre Vascular Inc.

LMAT

LeMaitre Vascular Inc.

HOLD

Current Price

$86.13

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
LMAT
Founded
2017
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
2020
2006

Fundamental Metrics

Financial Performance
Metric
HRMY
LMAT
Price
$38.49
$86.13
Analyst Decision
Strong Buy
Buy
Analyst Count
9
6
Target Price
$51.33
$101.83
AVG Volume (30 Days)
779.7K
211.9K
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
0.94%
EPS Growth
50.44
27.40
EPS
3.17
2.32
Revenue
$825,944,000.00
$240,866,000.00
Revenue This Year
$23.11
$15.17
Revenue Next Year
$16.15
$9.07
P/E Ratio
$11.94
$36.62
Revenue Growth
21.13
13.07
52 Week Low
$25.52
$71.42
52 Week High
$40.93
$105.55

Technical Indicators

Market Signals
Indicator
HRMY
LMAT
Relative Strength Index (RSI) 60.94 55.08
Support Level $37.12 $82.52
Resistance Level $40.87 $87.09
Average True Range (ATR) 1.38 2.49
MACD -0.33 0.40
Stochastic Oscillator 50.62 68.36

Price Performance

Historical Comparison
HRMY
LMAT

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.

Share on Social Networks: